EXECUTIVE ENGAGEMENTS
POOL
872
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
174
Interactions with Platform & by Email
PARTICIPANTS
33
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
44
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
193
EDITION
8
PRICE
USD 4950
CODE
MCP10868
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
Global Cancer/Tumor Profiling Market to Reach $10.7 Billion by 2026
Amid the COVID-19 crisis, the global market for Cancer/Tumor Profiling estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$10.7 Billion by 2026, growing at a CAGR of 9.3% over the analysis period. Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybridization segment is readjusted to a revised 9.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $2.1 Billion in 2021, While China is Forecast to Reach $1.9 Billion by 2026
The Cancer/Tumor Profiling market in the U.S. is estimated at US$2.1 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2026 trailing a CAGR of 8.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.
Next Generation Sequencing Segment to Reach US$1.9 Billion by the year 2026
In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$864.8 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
SELECT PLAYERS
Caris Life Sciences; Genomic Health, Inc.; Helomics Corporation; HTG Molecular Diagnostics, Inc.; Illumina, Inc.; Nanostring Technologies, Inc.; NeoGenomics Laboratories, Inc.; Oxford Gene Technology; Qiagen NV; Ribomed Biotechnologies, Inc.
SEGMENTS
» Application (Clinical Application, Research Application) » Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer Types) » Technology (Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry, Other Technologies (Pyrosequencing and Sanger Sequencing))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Cancer/Tumor Profiling: Market Overview & Outlook |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Increasing Incidence of Cancer Worldwide: Primary Growth Driver |
| EXHIBIT: Cancer Rates (100,000 People) in Select Countries: 2021 |
| EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
| EXHIBIT: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020 |
| The United States: Characterized by Higher Incidence of Cancer |
| EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
| EXHIBIT: Estimated New Cases for Selected Cancers in the US by State: 2020 |
| Enhanced Use of Biomarkers in Tumor Profiling Bodes Well |
| Cancer Research & Funding Initiatives Augment Market Prospects |
| Growing Role of Personalized Medicine Augurs Well |
| Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 44 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com